We recently reported that loss of mutant IDH1 expression is not sufficient to repress tumor growth derived from immortalized human astrocytes expressing doxycycline-inducible mutant IDH1 [53], thus suggesting that IDH1 mutation is dispensable for glioma progression and maintenance. This evidence concerns the gene IDH1 and central nervous system cancer.